These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10634985)

  • 21. Nissen fundoplication and pyloroplasty in the management of gastro-oesophageal reflux in children.
    Davidson BR; Hurd DM; Johnstone MS
    Br J Surg; 1987 Jun; 74(6):488-90. PubMed ID: 3607405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapy of gastro-oesophageal reflux disease in children: focus on safety.
    Vandenplas Y; Badriul H; Salvatore S; Hauser B
    Expert Opin Drug Saf; 2002 Nov; 1(4):355-64. PubMed ID: 12904135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisapride decreases gastroesophageal reflux in preterm infants.
    Ariagno RL; Kikkert MA; Mirmiran M; Conrad C; Baldwin RB
    Pediatrics; 2001 Apr; 107(4):E58. PubMed ID: 11335779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of prokinetics in children with recurrent nocturnal retrosternal pain.
    Hegar B; de Pont S; Vandemaele K; Vandenplas Y
    Eur J Gastroenterol Hepatol; 1998 Jul; 10(7):565-8. PubMed ID: 9855079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nissen fundoplication and gastrostomy in severely neurologically impaired children with gastroesophageal reflux.
    Cheung KM; Tse HW; Tse PW; Chan KH
    Hong Kong Med J; 2006 Aug; 12(4):282-8. PubMed ID: 16912355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease.
    Gardner JD; Rodriguez-Stanley S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1819-29. PubMed ID: 12269977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome 5 years after 360 degree fundoplication for gastro-oesophageal reflux disease.
    Johansson J; Johnsson F; Joelsson B; Florén CH; Walther B
    Br J Surg; 1993 Jan; 80(1):46-9. PubMed ID: 8428292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oesophageal pH monitoring and reflux oesophagitis in irritable infants.
    Vandenplas Y; Badriul H; Verghote M; Hauser B; Kaufman L
    Eur J Pediatr; 2004 Jun; 163(6):300-4. PubMed ID: 15346910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of a defective lower esophageal sphincter in the clinical outcome of treatment for gastroesophageal reflux disease.
    Costantini M; Zaninotto G; Anselmino M; Boccù C; Nicoletti L; Ancona E
    Arch Surg; 1996 Jun; 131(6):655-9. PubMed ID: 8645075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2006 Sep; 38(9):643-8. PubMed ID: 16627016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastro-oesophageal reflux disease.
    Moayyedi P; Delaney B; Forman D
    Clin Evid; 2003 Jun; (9):496-512. PubMed ID: 12967375
    [No Abstract]   [Full Text] [Related]  

  • 33. Routine management of gastro-oesophageal reflux disease by gastroenterologists in France: a prospective observational study.
    Bretagne JF; Rey JF; Caekaert A; Barthélemy P
    Dig Liver Dis; 2005 Aug; 37(8):566-70. PubMed ID: 15886080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study.
    Peters FT; Ganesh S; Kuipers EJ; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
    Gut; 1999 Oct; 45(4):489-94. PubMed ID: 10486353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
    Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
    Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of gastro-oesophageal reflux disease. Are there alternatives to omeprazole?
    Meuwissen SG; Klinkenberg-Knol EC
    Digestion; 1989; 44 Suppl 1():54-62. PubMed ID: 2575062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastroesophageal reflux in infants and children.
    Jung AD
    Am Fam Physician; 2001 Dec; 64(11):1853-60. PubMed ID: 11764863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reflux esophagitis in infants and children: a report from the Working Group on Gastro-Oesophageal Reflux Disease of the European Society of Paediatric Gastroenterology and Nutrition.
    Vandenplas Y
    J Pediatr Gastroenterol Nutr; 1994 May; 18(4):413-22. PubMed ID: 7915307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological management of gastro-oesophageal reflux disease.
    Klinkenberg-Knol EC; Festen HP; Meuwissen SG
    Drugs; 1995 May; 49(5):695-710. PubMed ID: 7601011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
    Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.